Veeda Clinical Research Acquires European CRO Heads

Headlands Research Acquires Clinvest Research

May 4, 2023

Healthcare Services

Headlands Research, a multinational clinical trial site network, has acquired Clinvest Research, a Springfield, Missouri-based clinical research site that has conducted over 600 trials since 1996. The deal expands Headlands' chronic pain and endocrinology capabilities and increases participant access for trials in the United States.

Rho Acquires Dokumeds

December 8, 2021

Healthcare Services

Rho, a privately held full-service contract research organization (CRO) based in Research Triangle Park/Durham, North Carolina, has acquired Dokumeds, a privately held European CRO headquartered in Riga, Latvia. The acquisition expands Rho's global footprint and clinical development capabilities, providing clients broader access to patients and multinational trial support; terms were not disclosed.

Alira Health Acquires Sourcia

April 5, 2022

Healthcare Services

Alira Health has acquired Sourcia, a Europe-based full-service Contract Research Organization (CRO) focused on Phase I–IV clinical trials for biotech, medical devices, and digital therapeutics. The deal expands Alira Health's clinical operations footprint into Central Europe, adding Sourcia's offices in Zevenbergen (Netherlands), Munich (Germany) and Vienna (Austria) to its capabilities.

Headlands Research Acquires Clinical Research Professionals (St. Louis)

October 12, 2023

Healthcare Services

Headlands Research has acquired Clinical Research Professionals, a St. Louis–area clinical research site, expanding Headlands' network and geographic reach. The acquisition adds experienced investigators and capabilities across therapeutic areas including gastroenterology, neurology, and vaccines, supporting increased participant recruitment and trial capacity.

Avance Clinical Acquires C3 Research Associates to Expand into North America

September 6, 2022

Healthcare Services

Avance Clinical, a PE-backed Australian CRO, has acquired North American CRO partner C3 Research Associates to expand its later‑phase clinical trial capabilities and establish a US presence. Backed by private equity firm The Riverside Company, Avance will integrate C3 into its GlobalReady model and invest in growing its North American team to support biotechs transitioning from early‑phase studies in Australia/New Zealand to later phases in the US.

GHO Capital Acquires Velocity Clinical Research

July 15, 2021

Healthcare Services

Global Healthcare Opportunities (GHO) has acquired Durham-based Velocity Clinical Research from NaviMed Capital and other investors. GHO intends to support Velocity’s roll-up strategy of clinical trial sites, expand its integrated site model (including investment in technology and decentralized trial capabilities) and pursue further geographic expansion, including into Europe.